Professor Nicholas James, Director of the Cancer Research Unit at the University of Warwick and Consultant in Clinical Oncology at University Hospitals Birmingham NHS Foundation Trust indicated that Abiraterone, Known as Zytiga can improve survival of advanced prostate cancer by 37% if the drug is combined with standard therapy. Abiraterone stops testosterone reaching the prostate